Scholars@Duke publication: Examining Healthcare Resource Utilization (HCRU) and Costs in US Patients Diagnosed with Relapsed Acute Myeloid Leukemia (AML)

Examining Healthcare Resource Utilization (HCRU) and Costs in US Patients Diagnosed with Relapsed Acute Myeloid Leukemia (AML)

Conferences

Tabah, A; Knoth, R; Huggar, D; Copher, RM; Cao, Z; Lipkin, C; Leblanc, TW

Published in: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

September 2020

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

2152-2669

2152-2650

September 2020

S181 / S181

APA

Chicago

ICMJE

MLA

NLM

Tabah, A., Knoth, R., Huggar, D., Copher, R. M., Cao, Z., Lipkin, C., & Leblanc, T. W. (2020). Examining Healthcare Resource Utilization (HCRU) and Costs in US Patients Diagnosed with Relapsed Acute Myeloid Leukemia (AML). In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 20, pp. S181–S181).

Tabah, Ashley, Russell Knoth, David Huggar, Ronda M. Copher, Zhun Cao, Craig Lipkin, and Thomas W. Leblanc. “Examining Healthcare Resource Utilization (HCRU) and Costs in US Patients Diagnosed with Relapsed Acute Myeloid Leukemia (AML).” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 20:S181–S181, 2020.

Tabah A, Knoth R, Huggar D, Copher RM, Cao Z, Lipkin C, et al. Examining Healthcare Resource Utilization (HCRU) and Costs in US Patients Diagnosed with Relapsed Acute Myeloid Leukemia (AML). In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020. p. S181–S181.

Tabah A, Knoth R, Huggar D, Copher RM, Cao Z, Lipkin C, Leblanc TW. Examining Healthcare Resource Utilization (HCRU) and Costs in US Patients Diagnosed with Relapsed Acute Myeloid Leukemia (AML). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020. p. S181–S181.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

2152-2669

2152-2650

September 2020

S181 / S181